SCHEMBL4469097

SCHEMBL4469097

CC(C(O)c1ccccc1)N1CCN(Cc2ccc(Cl)cc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.58
ADORA3 P0DMS8 2/20 0.57
CNR1 P21554 2/20 0.57
HRH1 P35367 2/20 0.57
OPRK1 P41145 2/20 0.57
KCNH2 Q12809 2/20 0.57
GHSR Q92847 2/20 0.57
LMNA P02545 2/20 0.57
NR1I2 O75469 1/20 0.57
PDE4D Q08499 1/20 0.57
CYP3A4 P08684 2/20 0.53
USP2 O75604 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
HPN P05981 1/20 0.53
CHRM2 P08172 1/20 0.53
ADRA2A P08913 1/20 0.53
CHRM1 P11229 1/20 0.53
DRD2 P14416 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473753 0.92 KDM4E (0.59) SIGMAR1HRH1OPRK1KCNH2LMNA
SCHEMBL12464946 0.79 KCNH2 (0.80) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL11820910 0.78 SIGMAR1 (0.56) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL7097618 0.78 ALDH1A1 (0.54) ADORA3CNR1HRH1OPRK1KCNH2
Hydrochloric Acid SCHEMBL11820828 0.78 SIGMAR1 (0.55) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL4474175 0.77 KDM4E (0.82) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL18704989 0.76 GRIN2B (0.52) SIGMAR1HRH1OPRK1KCNH2LMNA
SCHEMBL14983598 0.76 SIGMAR1 (0.61) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL9720751 0.76 KCNH2 (0.71) SIGMAR1ADORA3CNR1HRH1OPRK1
SCHEMBL3611802 0.76 KCNH2 (0.78) SIGMAR1ADORA3CNR1HRH1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576086-B2 N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2009-08-18 US claimed
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2005-12-01 US claimed
US-7576086-B2 N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2009-08-18 US disclosed
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant AANAT, GAP43, TPH2 SIGMAR1 805/4885ADORA3 18/4885CNR1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.